Use of Genomics to Track Coronavirus Disease Outbreaks, New Zealand.

2019 novel coronavirus disease COVID-19 New Zealand SARS-CoV-2 coronavirus disease genomics infectious disease respiratory infections severe acute respiratory syndrome coronavirus 2 viruses zoonoses

Journal

Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155

Informations de publication

Date de publication:
05 2021
Historique:
entrez: 26 4 2021
pubmed: 27 4 2021
medline: 22 6 2021
Statut: ppublish

Résumé

Real-time genomic sequencing has played a major role in tracking the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), contributing greatly to disease mitigation strategies. In August 2020, after having eliminated the virus, New Zealand experienced a second outbreak. During that outbreak, New Zealand used genomic sequencing in a primary role, leading to a second elimination of the virus. We generated genomes from 78% of the laboratory-confirmed samples of SARS-CoV-2 from the second outbreak and compared them with the available global genomic data. Genomic sequencing rapidly identified that virus causing the second outbreak in New Zealand belonged to a single cluster, thus resulting from a single introduction. However, successful identification of the origin of this outbreak was impeded by substantial biases and gaps in global sequencing data. Access to a broader and more heterogenous sample of global genomic data would strengthen efforts to locate the source of any new outbreaks.

Identifiants

pubmed: 33900175
doi: 10.3201/eid2705.204579
pmc: PMC8084492
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1317-1322

Références

Virus Evol. 2020 Apr 10;6(1):veaa027
pubmed: 32296544
Transbound Emerg Dis. 2020 Jul;67(4):1453-1462
pubmed: 32306500
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Nucleic Acids Res. 2019 Jul 2;47(W1):W256-W259
pubmed: 30931475
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Lancet Infect Dis. 2020 Apr;20(4):400-402
pubmed: 32113509
Science. 2020 Oct 30;370(6516):571-575
pubmed: 32913002
Lancet Public Health. 2020 Nov;5(11):e612-e623
pubmed: 33065023
PLoS Comput Biol. 2019 Apr 8;15(4):e1006650
pubmed: 30958812
Biol Methods Protoc. 2020 Jul 18;5(1):bpaa014
pubmed: 33029559
Nat Med. 2020 Sep;26(9):1398-1404
pubmed: 32647358
Nat Commun. 2020 Dec 11;11(1):6351
pubmed: 33311501
Nat Med. 2020 Sep;26(9):1405-1410
pubmed: 32678356
Nat Nanotechnol. 2020 Aug;15(8):646-655
pubmed: 32669664
Science. 2020 Sep 4;369(6508):1255-1260
pubmed: 32703910
Mol Biol Evol. 2005 May;22(5):1185-92
pubmed: 15703244
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
PLoS Biol. 2020 Aug 21;18(8):e3000869
pubmed: 32822393

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH